Save the Date for CIMT 2022
The 2022 CIMT Annual Meeting will take place May 10-12, 2022. More information will be posted as it becomes available.
Stay up-to-date on CIMT news and events: subscribe to our newsletter.
On-demand viewing is available
The 2021 Annual Meeting sessions and eTalks have been available for on-demand viewing on the virtual event platform since May 31. To access the platform, conference participants use the same login data used to access the conference.
- The lectures and eTalks are available on-demand in the respective virtual rooms through the end of June.
- The virtual industry exhibition is also still accessible.
- If a speaker did not consent to the on-demand format, the presentation is not included.
If you have any further questions or requirements, please feel free to contact us. You may reach us by phone: +49 (0) 611 204809-240 or via email: email@example.com.
ACIR meeting summary
Selected talks from the virtual 18th CIMT Annual Meeting, including the keynote lecture by Ugur Sahin, were covered by ACIR. The meeting summary can be accessed on the ACIR web page.
CIMT thanks the ACIR team for their coverage of this year's virtual Annual Meeting.
Accelerating Cancer Immunotherapy Research (ACIR) publishes weekly, free-of-charge and readily accessible synopses of the key advances in the fast moving and multifaceted field of cancer immunotherapy. For more information see https://acir.org
Read the report of the 18th CIMT Annual Meeting at https://acir.org/weekly-digests/2021/may/cimt-annual-meeting-2021#keynote
On-demand session viewing
The Annual Meeting virtual platform is currently under construction. Thank you for your patience while we are preparing the session talks for on-demand viewing. The platform will re-open at the end of May.
All registered participants of the CIMT Annual Meeting will have continued access to the virtual meeting platform where eTalks and session talks can be viewed on-demand through the end of June.
2021 eTalk Award Winners
Six early-career researchers have been chosen by the CIMT poster jury to receive the 2021 CIMT Poster Awards. One eTalk winner was selected by the meeting audience.:
We congratulate Alejandro Hernandez-Sanchez (German Cancer Research Center), Paola Bonaventura (Cancer Research Center of Lyon), Leonie Rosenberger (Charité-Universitätsmedizin ), Miro Raeber (University Hospital Zurich), Marie Christine Viuff (Technical University of Denmark), Francesca Simoncello (International Centre for Genetic Engineering and Biotechnology)
Mutation-specific T cell receptors from tumor-bearing hosts display optimal functionality
German Cancer Research Center-DKFZ
Immunogenicity and HLA binding affinity of MSI-associated frameshift peptide neoantigens
New Targets and New Leads
Cancer Research Center of Lyon
Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy
Marie Christine Viuff
Technical University of Denmark
Mapping of HPV-specific CD8+ T cells and immune signatures in cervical intraepithelial neoplasia and cancer
Tumor Biology & Interaction with the Immune System
International Centre for Genetic Engineering and Biotechnology
CXCL5-mediated accumulation of SiglecFhigh neutrophils in lung tumor tissues impairs CD8 T cell responses and limits the efficacy of PD-L1 checkpoint blockade
University Hospital Zurich
Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity
Regensburg Center for Interventional Immunology (RCI)
The serine/threonine kinase CAMK1D confers immune resistance of PD-L1 refractory tumor cells against tumor-reactive cytotoxic T cells
We would like to thank Immatics Biotechnologies for their generous support of the 2021 eTalk Awards.
CIMT 2021 opens in Mainz, Germany
The virtual 18th Annual Meeting of the Association for Cancer Immunotherapy CIMT was opened today by CIMT President Özlem Türeci with over 800 cademic and clinical professionals in the fields of tumor immunology attending online. Over 220 submitted abstracts are presented online as eTalks.
The 2021 meeting offers eight plenary plenary sessions offers sessions on topics such as cellular therapy, neontigens/vaccines, immunoguiding, tumor microenvironment, microbiota, bioinformatics, improving immunity, and regulatory research, plus a special COVID-19−Immuno-Oncology Cross Talk session.
2021 abstracts are online
All abstracts and the day-to-day 2021 Annual Meeting program are online can be accessed at www.meeting.cimt.eu/program.
During the meeting, the abstracts and day-to-day program can be viewed on the virtual meetig platform.
2021 CIMT Lifetime Achievement Award
The Italian immunologist Alberto Mantovani will be honored by CIMT for life-time achievements in cancer immunotherapy research. The prize will be awarded on the evening of Monday, May 10 at 7 p.m., as part of the virtual Annual Meeting of the Association for Cancer Immunotherapy CIMT, May 10-12, 2021.
On May 10, 2021, the Italian immunologist Alberto Mantovani will be honored for life-time achievements in cancer immunotherapy research. The prize, which is awarded every other year by the Association for Cancer Immunotherapy CIMT, honors European scientists who have made significant contributions to cancer immunotherapy research over their careers. Alberto Mantovani is Emeritus Professor of Pathology at the Humanitas University in Milan, and Scientific Director of the Istituto Clinico Humanitas.
Over his 50-year career, Alberto Mantovani, an expert on the molecular mechanisms of innate immunity and inflammation, has significantly advanced knowledge in the field of immunology by formulating new paradigms and identifying new molecules and functions. In addition, he has furthered awareness of science and medicine by authoring books and articles on immunology, vaccines and health targeted at the general public.
Abstract authors have been notified
All abstract authors have been notified and have been sent information about setting up their presentations. The CIMT eTalk sessions will feature a total of 221 scientific eTalks.
All eTalks will be available for on-demand viewing via the conference platform from May 10 through June 12, 2021. All accepted abstract texts will be included in the online program book and will be published online on May 3.
During their eTalk Session, all abstract presenters can engage with conference participants in personal Q&A chat rooms.
All eTalk presenters have the chance to be selected for best eTalk in their category. The eTalk awards will be presented at the closing of the conference (May 12, 6:30-7:00 pm).
The 2021 eTalk awards are supported by Immatics.
Abstract submission extended to March 24
For late breaking abstracts, the 2021 abstract submission and advance registration has been extended to March 24 (midnight CET).
Submit your abstract in the following categories: · Therapeutic Vaccination · Immunomonitoring · Cellular Therapy · New Targets & New Leads · Tumor Biology and Interaction with the Immune System · Improving Immunity
Apply for a registration waiver
CIMT will select young scientists from underrepresented countries for free conference admission. Free conference admission can only be extended to scientists who have submitted an abstract and are registered to attend the meeting.
In previous years, travel award winners came from Argentina, Turkey, Hungary, Greece, Portugal, Czech Republic, Cuba, Chile, Poland, India, Egypt, among others.
Go to www.meeting.cimt.eu/travel-awards for more information.
2021 registration and abstract submission is open
For its virtual congress, the CIMT program committee is calling for abstract submission in six categories: Therapeutic Vaccination, Cellular Therapy, New Targets and New Leads, Immunomonitoring, Tumor Biology and Interaction with the Immune System, Improving Immunity.
The abstract submission deadline is set for March 14, 2021.
All abstract authors/presenters must register for the conference prior to submitting an abstract.
2021 CIMT Annual Meeting
Save the date for the 2021 CIMT Annual Meeting which will take place in a virtual format, from May 10-12, 2021. CIMT will take the opportunity to provide international participants with high-level scientific learning and knowledge exchange regardless of their location or travel restrictions. We will post more information as soon as it becomes available.
To receive timely notification on the 2021 call for abstracts and other conference information, please consider signing up for our newsletter.
The 2020 CIMT Annual Meeting will not take place
The CIMT Executive Board has decided to not hold the CIMT Annual Meeting, which was scheduled for May 5-7, 2020, in Mainz, Germany. This decision was made after considering current information, guidance and forecasts issued by the German federal and regional governments concerning the novel coronavirus pandemic. We also took into consideration the worldwide travel and gathering restrictions which have been put in place and the yet unforeseeable duration of these measures.
Ensuring the health and safety of our participants, staff and the greater community is our first priority.
No alternative date has been scheduled at this point in time, but we will look into opportunities to hold the meeting later this year.
For now, CIMT will refund all registration and exhibitor fees in full.
Refunds will take several weeks. We would like to thank you in advance for your patience.
If you have any questions, please contact CIMT by email at firstname.lastname@example.org.
The Association for Cancer Immunotherapy
Welcome to Europe’s largest meeting focused on cancer immunotherapy research and development.
CIMT is a members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. CIMT was founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine as an independent non-profit organization. CIMT has its offices in Mainz, Germany, and is financed by donations, congress fees, industry sponsorship and by public and foundation grants.